Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Receptor Logic
Abilene, Texas, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
Receptor Logic develops T cell receptor mimic (TCRm) antibodies that target HLA-presented tumor peptides, enabling selective targeting of cancer cells while sparing healthy tissue. The company’s leading candidate, RL-6A, is in early development for breast cancer, and a TCRm monoclonal antibody against NY-ESO1 has been exclusively licensed to Xencor for cancer therapy[1][2][7].
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyAntibodyT cell receptor mimic
- Industry
- Biotech
02
Partnerships
Xencor (exclusive license for NY-ESO1 TCRm monoclonal antibody in oncology)
Beyond the preview
Go deeper on Receptor Logic.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Receptor Logic.